Warning shareholders that the strategy to handle $620 million in debt due in 2016 could result in their ending up with "little or no ownership," Dendreon Corp. reported second-quarter earnings that showed the prostate cancer (PC) drug Provenge (sipuleucel-T) gaining 12 percent in sales year over year and 19 percent quarter over quarter, reaching $82 million.